-
1
-
-
0025869955
-
Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors
-
Merchav S, Wagemaker G, Souza LM, Tatarsky I. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haemopoietic growth factors. Leukemia 1991; 5: 340-346.
-
(1991)
Leukemia
, vol.5
, pp. 340-346
-
-
Merchav, S.1
Wagemaker, G.2
Souza, L.M.3
Tatarsky, I.4
-
2
-
-
0029020851
-
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
-
Raza A, Gezer S, Mundle S et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268-276.
-
(1995)
Blood
, vol.86
, pp. 268-276
-
-
Raza, A.1
Gezer, S.2
Mundle, S.3
-
3
-
-
0642349138
-
Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells
-
Acosta JC, Richard C, Delgado MD et al. Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther 2003; 2: 893-900.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 893-900
-
-
Acosta, J.C.1
Richard, C.2
Delgado, M.D.3
-
4
-
-
0029745368
-
Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by armfostine (Ethyol)
-
Capizzi, R. L. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by armfostine (Ethyol). Eur J Cancer 1996; 23: 2-17.
-
(1996)
Eur J Cancer
, vol.23
, pp. 2-17
-
-
Capizzi, R.L.1
-
5
-
-
0033057234
-
Ex vivo manipulation of hematopoietic stem cells for transplantation: The potential role of amifostine
-
Balzarotti M, Grisanti S, Granzow K et al. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine. Semin Oncol 1999; 26: 66-71.
-
(1999)
Semin Oncol
, vol.26
, pp. 66-71
-
-
Balzarotti, M.1
Grisanti, S.2
Granzow, K.3
-
6
-
-
12944332006
-
Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin
-
Preisler HD, Li B, Yang BL et al. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin. Clin Cancer Res 2000; 6: 807-812.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 807-812
-
-
Preisler, H.D.1
Li, B.2
Yang, B.L.3
-
7
-
-
0031683421
-
Negative selection and protection of normal progenitor cells for autografting
-
Douay L. Negative selection and protection of normal progenitor cells for autografting. Bone Marrow Transplant 1998; 22: 423-430.
-
(1998)
Bone Marrow Transplant
, vol.22
, pp. 423-430
-
-
Douay, L.1
-
8
-
-
0034161542
-
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
-
Raza A, Qawi H, Lisak L et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000; 95: 1580-1587.
-
(2000)
Blood
, vol.95
, pp. 1580-1587
-
-
Raza, A.1
Qawi, H.2
Lisak, L.3
-
9
-
-
0030735082
-
Stimulation of hematopoiesis by amifostine in patients with myelodysplastic, syndromes
-
List AF, Brasfield F, Heaton R et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic, syndromes. Blood 1997; 90: 3364-3369.
-
(1997)
Blood
, vol.90
, pp. 3364-3369
-
-
List, A.F.1
Brasfield, F.2
Heaton, R.3
-
10
-
-
0030664927
-
Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration
-
Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997; 99: 625-631.
-
(1997)
Br J Haematol
, vol.99
, pp. 625-631
-
-
Peddie, C.M.1
Wolf, C.R.2
McLellan, L.I.3
Collins, A.R.4
Bowen, D.T.5
-
11
-
-
0022655609
-
WR-2721 protects against tne hematologic toxicity of cyclophosphamide: A controlled phase 11 trial
-
Glover D, Glick JH, Weiler C, Hurowitz S, Kligermann MM. WR-2721 protects against tne hematologic toxicity of cyclophosphamide: a controlled phase 11 trial. J Clin Oncol 1986; 4: 574-578.
-
(1986)
J Clin Oncol
, vol.4
, pp. 574-578
-
-
Glover, D.1
Glick, J.H.2
Weiler, C.3
Hurowitz, S.4
Kligermann, M.M.5
-
12
-
-
0031705387
-
Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors
-
List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 1998; 12; 1596-1602.
-
(1998)
Leukemia
, vol.12
, pp. 1596-1602
-
-
List, A.F.1
Heaton, R.2
Glinsmann-Gibson, B.3
Capizzi, R.L.4
-
13
-
-
0034072875
-
Amifostine in the treatment of low-risk myelodysplastic syndromes
-
Grossi A, Fabbri A, Santini V et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 2000; 85: 367-371.
-
(2000)
Haematologica
, vol.85
, pp. 367-371
-
-
Grossi, A.1
Fabbri, A.2
Santini, V.3
-
14
-
-
0343238131
-
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
-
Hofmann WK, Seipelt G, Ottmann OG et al. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Ann Hematol 2000; 79: 255-258.
-
(2000)
Ann Hematol
, vol.79
, pp. 255-258
-
-
Hofmann, W.K.1
Seipelt, G.2
Ottmann, O.G.3
-
15
-
-
0035138109
-
Arnifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome
-
Tefferi A, Elliott MA, Steensma DP et al. Arnifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res 2001; 25: 183-185.
-
(2001)
Leuk Res
, vol.25
, pp. 183-185
-
-
Tefferi, A.1
Elliott, M.A.2
Steensma, D.P.3
-
16
-
-
0035033017
-
-
Neumeister P, Jaeger G, Eib1 M, Sormann S, Zinke W, Linkesch W. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodys-plastic syndrome. Leuk Lymphoma 2001; 40: 345-349.
-
Neumeister P, Jaeger G, Eib1 M, Sormann S, Zinke W, Linkesch W. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodys-plastic syndrome. Leuk Lymphoma 2001; 40: 345-349.
-
-
-
-
17
-
-
0035010102
-
Treatment of patients with myelodysplastic syndrome with amifostine
-
Galanopoulos A, Kritikou-Griva E, Gligori J et al. Treatment of patients with myelodysplastic syndrome with amifostine. Leuk Res 2001; 25: 665-671.
-
(2001)
Leuk Res
, vol.25
, pp. 665-671
-
-
Galanopoulos, A.1
Kritikou-Griva, E.2
Gligori, J.3
|